<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-181 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-181</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-181</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-7.html">extraction-schema-7</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of specific cell types in Alzheimer's disease that are described as susceptible or resilient, the evidence for this classification, and any proposed mechanisms or factors explaining their susceptibility or resilience.</div>
                <p><strong>Paper ID:</strong> paper-df4cf65ac1fc2a7bc7a7c6998c738639e43a684c</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/df4cf65ac1fc2a7bc7a7c6998c738639e43a684c" target="_blank">Proteomic signatures of brain regions affected by tau pathology in early and late stages of Alzheimer's disease</a></p>
                <p><strong>Paper Venue:</strong> Neurobiology of Disease</p>
                <p><strong>Paper TL;DR:</strong> The comparison of proteomic changes in brain regions affected by tau pathology at different stages of AD is provided, and it is found that the dysregulated processes are predominantly region specific.</p>
                <p><strong>Cost:</strong> 0.014</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e181.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e181.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of specific cell types in Alzheimer's disease that are described as susceptible or resilient, the evidence for this classification, and any proposed mechanisms or factors explaining their susceptibility or resilience.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Neuron</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Neuron (neuronal/synaptic compartments)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Neurons are reported as the primary cell type undergoing synaptic dysfunction and loss in Alzheimer's disease (AD), reflected by broad down-regulation of synaptic, dendritic and axonal proteins across multiple brain regions.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Proteomic signatures of brain regions affected by tau pathology in early and late stages of Alzheimer's disease</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>cell_type</strong></td>
                            <td>Neuron</td>
                        </tr>
                        <tr>
                            <td><strong>susceptibility_status</strong></td>
                            <td>susceptible</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_status</strong></td>
                            <td>Mass-spectrometry proteomics from human postmortem brain showed a global down-regulation of synaptic proteins and components of axons/dendrites in all four analyzed regions (entorhinal cortex, parahippocampal cortex, temporal cortex, frontal cortex); synapse-related GO categories were significantly depleted and synapse loss is stated as an early and ubiquitous event in AD. Specific synaptic proteins (many listed in Table 1 and supplemental tables) were significantly decreased.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanisms</strong></td>
                            <td>Proposed mechanisms include toxic effects of soluble Aβ and tau on synapses (soluble tau and Aβ cause synaptic dysfunction), translation dysregulation (reduced ribosomal/translation proteins), impaired oxidative phosphorylation/mitochondrial dysfunction (energy failure particularly in medial temporal lobe), and region-specific high metabolic demand that predisposes synapses to degeneration; these factors are discussed as interacting (e.g., APOE influences APP/Aβ and mitochondrial complexes).</td>
                        </tr>
                        <tr>
                            <td><strong>experimental_context</strong></td>
                            <td>Human postmortem brain tissue proteomics (label-free LC-MS/MS; differential expression across Braak/Braak stages I-III vs IV-VI; PRM verification for selected proteins).</td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage</strong></td>
                            <td>Reported across early (Braak I-III) and late (Braak IV-VI) stages; synaptic protein down-regulation and synapse loss are observed already in early stages.</td>
                        </tr>
                        <tr>
                            <td><strong>contradictory_findings</strong></td>
                            <td>The paper notes that while the majority of shared DEPs show concordant direction across regions, a minority (~13 proteins of the 112 shared) changed in opposite directions between regions, indicating some region- and protein-specific heterogeneity in neuronal protein changes.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': "Proteomic signatures of brain regions affected by tau pathology in early and late stages of Alzheimer's disease", 'publication_date_yy_mm': '2019-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e181.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e181.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of specific cell types in Alzheimer's disease that are described as susceptible or resilient, the evidence for this classification, and any proposed mechanisms or factors explaining their susceptibility or resilience.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Astrocyte</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Astrocyte (reactive astrocytes indicated by GFAP upregulation)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Astrocyte-related signatures (notably GFAP up-regulation and enrichment of 'astrocyte development' GO terms) are increased in AD, reflecting reactive astrogliosis rather than clear cell loss, and APOE (major AD risk factor, produced by astrocytes) is more highly expressed in medial temporal lobe.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Proteomic signatures of brain regions affected by tau pathology in early and late stages of Alzheimer's disease</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>cell_type</strong></td>
                            <td>Astrocyte</td>
                        </tr>
                        <tr>
                            <td><strong>susceptibility_status</strong></td>
                            <td>unclear</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_status</strong></td>
                            <td>Proteomics show GFAP (a canonical astrocyte marker) among proteins up-regulated in multiple regions (Table 1 shows GFAP up in EC, PHC and FC, with larger increases at late stages); enrichment analysis identified 'astrocyte development' among up-regulated processes in entorhinal cortex clusters. APOE protein levels (measured and verified by PRM) are higher in medial temporal lobe (MTL) versus neocortex in controls and discussed as astrocyte-related.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanisms</strong></td>
                            <td>Astrocyte reactivity (increased GFAP) may be a response to neuronal/synaptic injury and Aβ/tau pathology; APOE produced by astrocytes is proposed to modulate APP transcription, Aβ production and tau toxicity (APOE isoforms differentially influence these pathways) and may link astrocyte biology, metabolism and regional vulnerability (MTL's higher APOE + high metabolic demand).</td>
                        </tr>
                        <tr>
                            <td><strong>experimental_context</strong></td>
                            <td>Human postmortem brain proteomics and targeted PRM verification (GFAP, APOE quantified across regions and stages).</td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage</strong></td>
                            <td>GFAP up-regulation and astrocyte-development GO enrichment are reported in both early and late B/B stages (GFAP increases are larger in late stages but detectable earlier in some regions).</td>
                        </tr>
                        <tr>
                            <td><strong>contradictory_findings</strong></td>
                            <td>The paper does not report astrocyte loss; rather reactive up-regulation. There is regional heterogeneity (magnitude of GFAP increase varies by region). No direct evidence in this study that astrocytes are selectively resistant (resilient) or selectively degenerate; the role is presented as reactive and potentially contributory to vulnerability.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': "Proteomic signatures of brain regions affected by tau pathology in early and late stages of Alzheimer's disease", 'publication_date_yy_mm': '2019-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e181.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e181.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of specific cell types in Alzheimer's disease that are described as susceptible or resilient, the evidence for this classification, and any proposed mechanisms or factors explaining their susceptibility or resilience.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Bergmann glia</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Bergmann glial cells (specialized cerebellar astrocytes) </td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A Gene Ontology enrichment term ('Bergmann glial cell differentiation') appears among biological processes enriched in an early up-regulated cluster in the entorhinal cortex, noted by the authors during cluster enrichment analysis.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Proteomic signatures of brain regions affected by tau pathology in early and late stages of Alzheimer's disease</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cell_type</strong></td>
                            <td>Bergmann glia (glial subtype)</td>
                        </tr>
                        <tr>
                            <td><strong>susceptibility_status</strong></td>
                            <td>unclear</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_status</strong></td>
                            <td>Presence of the GO term 'Bergmann glial cell differentiation' among enriched biological processes in an early-up cluster for entorhinal cortex (reported in Fig. 3 / enrichment outputs). This is an annotation/enrichment signal rather than direct measurement of Bergmann glial protein markers.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanisms</strong></td>
                            <td>No mechanism is proposed in the paper specifically for Bergmann glia; the term appears in enrichment outputs and likely reflects shared molecular pathways related to glial differentiation or intermediate filament organization rather than direct evidence of Bergmann glia involvement.</td>
                        </tr>
                        <tr>
                            <td><strong>experimental_context</strong></td>
                            <td>Human postmortem proteomics with GO enrichment analysis of differentially expressed protein clusters.</td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage</strong></td>
                            <td>Early Braak/Braak stages (the GO term appears in an 'early-up' cluster in entorhinal cortex).</td>
                        </tr>
                        <tr>
                            <td><strong>contradictory_findings</strong></td>
                            <td>None reported in this paper; inclusion arises from enrichment analysis and is not followed by cell-type specific validation, so it should be interpreted cautiously.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': "Proteomic signatures of brain regions affected by tau pathology in early and late stages of Alzheimer's disease", 'publication_date_yy_mm': '2019-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Profiling the human hippocampal proteome at all pathologic stages of Alzheimer's disease <em>(Rating: 2)</em></li>
                <li>A multi-network approach identifies protein-specific co-expression in asymptomatic and symptomatic Alzheimer's disease <em>(Rating: 2)</em></li>
                <li>Pathological tau promotes neuronal damage by impairing ribosomal function and decreasing protein synthesis <em>(Rating: 2)</em></li>
                <li>Soluble pathological tau in the entorhinal cortex leads to presynaptic deficits in an early Alzheimer's disease model <em>(Rating: 2)</em></li>
                <li>ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy <em>(Rating: 2)</em></li>
                <li>ApoE2, ApoE3, and ApoE4 differentially stimulate APP transcription and A beta secretion <em>(Rating: 2)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>